Paul Slesinger, PhD
- PROFESSOR | Neuroscience
Research Topics:
Addiction, Biophysics, Electrophysiology, Neurophysiology, Neuroscience, Protein Trafficking & Sorting, Signal Transduction, Synaptic PlasticityVisit Paul Slesinger's Laboratory of Membrane Excitability & Disease for more information.
Multi-Disciplinary Training Areas
Neuroscience [NEU], Pharmacology and Therapeutics Discovery [PTD]Education
BA, Reed College
PhD, University of California, San Francisco
Postdoctoral Fellow, University of California, San Francisco
-
2006
NARSAD Independent Investigator Award -
2003
McKnight Technological Innovations in Neuroscience Award -
2001
Human Frontiers Science Program Young Investigator Grant -
1999
McKnight Scholars Award in Neuroscience -
1998
Alfred P. Sloan Research Fellow
My long-term objective is to discover new drugs for treating addiction to drugs of abuse and alcohol. Currently, there are few FDA approved drugs for treating these diseases and more are greatly needed. Many of the neurotransmitters in the drug-reward pathway exert their effects by activating G protein-coupled receptors, which, in turn, communicate with specific G proteins and affect down-stream signaling pathways. One of the down-stream targets is the G protein-gated inwardly rectifying potassium (GIRK) channel, which we study in my laboratory. By controlling the membrane excitability of neurons, GIRK channels provide a fundamental source of neuromodulatory inhibition in the brain. My laboratory has been addressing fundamental questions concerning the function of GIRK channels in the brain, taking a broad approach of combining structural biology, biochemistry, electrophysiology and behavior. We have contributed significant work on the mechanism underlying G protein-regulation and gating of GIRK channels, provided evidence for the assembly of GIRK channels in macromolecular signaling complexes, and identified novel proteins that regulate GIRK channels. More recently, we have elucidated the subcellular mechanisms underlying the neuroplastic changes in GIRK channel signaling with drugs of abuse and alcohol. See lab web page for more details.
Lab Members:
Dr. Ian Glaaser (Postdoctoral Fellow)
Dr. Xiaofan Li (Postdoctoral Fellow)
Dr. Yulin Zhao (Postdoctoral Fellow)
Robert Rifkin (BSP: MD/PhD student)
Emre Lacin (Neuro: PhD student)
Tyler Kern (Neuro: master’s student)
Erin Aisenberg (Research technician)
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Slesinger did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.